Literature DB >> 27341269

Non-invasively differentiating extent of liver fibrosis by visualizing hepatic integrin αvβ3 expression with an MRI modality in mice.

Feng Li1, Huihui Yan2, Jiyao Wang3, Cong Li4, Jian Wu5, Shengdi Wu1, Shengxiang Rao6, Xihui Gao4, Qu Jin4.   

Abstract

AIMS: To explore the potential of a dendrimer nanoprobe labeled with cyclic arginine-glycine-aspartic acid pentapeptide (cRGDyK) as a magnetic resonance imaging (MRI) tracer to non-invasively differentiate the extent of liver fibrosis.
METHODS: Synthetic dendrimer nanoprobes were labeled with cRGDyK (Den-RGD) to form a formulation of hepatic stellate cell (HSC)-specific MRI tracer. An MRI modality was employed to visualize hepatic Den-RGD deposition in a mouse model of liver fibrosis caused by thioacetamide treatment.
RESULTS: Den-RGD bound to activated HSCs via integrin αvβ3 receptors. The labeling of nanoprobes with cRGDyK increased their affinity to and accelerated their uptake by activated HSCs. Most of intravenously administrated Den-RGD nanoprobes deposited in the fibrotic areas, and the deposited amount was paralleled with the severity of liver fibrosis. Majority of cells taking-up Den-RGD was found to be activated HSCs in fibrotic livers. An MRI modality using Den-RGD as a tracer demonstrated that the relative hepatic T1-weighed MR signal value was increased in parallel with the severity of liver fibrosis.
CONCLUSION: The extent of Den-RGD deposition reflects integrin αvβ3 expression in activated HSCs, and Den-RGD appears to be a useful formulation of MRI tracer and may non-invasively and quantitatively assess the extent of liver fibrosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatic stellate cells; Integrin αvβ3; Liver fibrosis; MRI modality; Nanoprobe

Mesh:

Substances:

Year:  2016        PMID: 27341269     DOI: 10.1016/j.biomaterials.2016.06.026

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

2.  The diagnosis of hepatic fibrosis by magnetic resonance and near-infrared imaging using dual-modality nanoparticles.

Authors:  Yunfang Li; Wenting Shang; Xiaoyuan Liang; Chaoting Zeng; Mingming Liu; Sudan Wang; Hongjun Li; Jie Tian
Journal:  RSC Adv       Date:  2018-02-12       Impact factor: 4.036

Review 3.  Application of Dendrimers in Anticancer Diagnostics and Therapy.

Authors:  Zuzanna Bober; Dorota Bartusik-Aebisher; David Aebisher
Journal:  Molecules       Date:  2022-05-18       Impact factor: 4.927

Review 4.  The Many Roles of Cell Adhesion Molecules in Hepatic Fibrosis.

Authors:  Edith Hintermann; Urs Christen
Journal:  Cells       Date:  2019-11-24       Impact factor: 6.600

Review 5.  Nanotechnology in Drug Delivery for Liver Fibrosis.

Authors:  Lihong Gu; Feng Zhang; Jinhui Wu; Yuzheng Zhuge
Journal:  Front Mol Biosci       Date:  2022-01-11

6.  Enhanced US/CT/MR imaging of integrin αvβ3 for liver fibrosis staging in rat.

Authors:  Xueyao Tang; Xuan Li; Mingxing Li; Xiaoling Zhong; Wenguang Fu; Meng Ao; Jiqing Xuan
Journal:  Front Chem       Date:  2022-10-03       Impact factor: 5.545

Review 7.  Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.

Authors:  Virender Kumar; Xiaofei Xin; Jingyi Ma; Chalet Tan; Natalia Osna; Ram I Mahato
Journal:  Adv Drug Deliv Rev       Date:  2021-07-24       Impact factor: 17.873

8.  Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy.

Authors:  Qiaohan Wang; Qi Zhao; Huangjin Tong; Mengting Yu; Meng Wang; Tulin Lu; Chengxi Jiang
Journal:  J Nanobiotechnology       Date:  2020-06-08       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.